Thursday, 15 October 2026European Markets

AERKOMM INC Stock Bearish Momentum With A 21% Slide In The Last 10 Sessions

Loading stream...

(vianews) - shares of aerkomm inc (cac 40: akom.pa) dropped by a staggering 21.67% in 10 sessions from €4.06 to €3.18 at 04:39 est on thursday, after five consecutive sessions in a row of losses. cac 40 is dropping 0.13% to €7,299.26, after four sequential sessions in a row of losses.

about aerkomm inc

aerkomm inc., together with its subsidiaries, focuses on providing in-flight entertainment and connectivity solutions in the asian pacific region. the company intends to offer airline passengers with broadband in-flight service options, such as wi-fi, cellular, movies, gaming, live tv, and music through built-in in-flight entertainment systems, such as seat-back displays, as well as on passengers' personal devices. it also focuses on providing content management services and e-commerce solutions; and aerkomm k++ system, a ifec system. the company is based in fremont, california.

earnings per share

as for profitability, aerkomm inc has a trailing twelve months eps of €-0.794.

more news about aerkomm inc (akom.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com